Compare Stocks: AVBP, XENE, LGND, and PTCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$27.97 -2.1%	$30.62	$17.00 ▼ $35.83	$1.41B	1.35	447,585 shs	337,267 shs
LGND Ligand Pharmaceuticals	$276.98 -1.3%	$293.30	$163.10 ▼ $326.63	$5.59B	1.11	180,081 shs	180,223 shs
PTCT PTC Therapeutics	$65.65 -1.2%	$73.51	$57.74 ▼ $90.87	$5.55B	0.55	799,539 shs	1.03 million shs
XENE Xenon Pharmaceuticals	$56.28 -3.3%	$63.24	$35.66 ▼ $72.66	$5.62B	0.61	596,192 shs	587,006 shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	-2.10%	-7.63%	-5.22%	-10.81%	+47.60%
LGND Ligand Pharmaceuticals	-1.31%	-4.10%	-5.98%	+5.26%	+67.35%
PTCT PTC Therapeutics	-1.25%	-4.59%	-8.44%	-16.40%	+11.31%
XENE Xenon Pharmaceuticals	-3.28%	-5.49%	-9.74%	+5.79%	+56.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$27.97 -2.1%	$30.62	$17.00 ▼ $35.83	$1.41B	1.35	447,585 shs	337,267 shs
LGND Ligand Pharmaceuticals	$276.98 -1.3%	$293.30	$163.10 ▼ $326.63	$5.59B	1.11	180,081 shs	180,223 shs
PTCT PTC Therapeutics	$65.65 -1.2%	$73.51	$57.74 ▼ $90.87	$5.55B	0.55	799,539 shs	1.03 million shs
XENE Xenon Pharmaceuticals	$56.28 -3.3%	$63.24	$35.66 ▼ $72.66	$5.62B	0.61	596,192 shs	587,006 shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	-2.10%	-7.63%	-5.22%	-10.81%	+47.60%
LGND Ligand Pharmaceuticals	-1.31%	-4.10%	-5.98%	+5.26%	+67.35%
PTCT PTC Therapeutics	-1.25%	-4.59%	-8.44%	-16.40%	+11.31%
XENE Xenon Pharmaceuticals	-3.28%	-5.49%	-9.74%	+5.79%	+56.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	2.70	Moderate Buy	$44.86	60.38% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$335.75	21.22% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$98.50	50.04% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$77.13	37.05% Upside

Current Analyst Ratings Breakdown

Latest AVBP, XENE, LGND, and PTCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	PTCT PTC Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$98.00
9/1/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/17/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/17/2026	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$44.00 ➝ $47.00
8/14/2026	PTCT PTC Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$120.00 ➝ $122.00
8/14/2026	LGND Ligand Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$330.00
8/13/2026	AVBP ArriVent BioPharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$43.00 ➝ $40.00
8/13/2026	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$106.00 ➝ $109.00
8/13/2026	AVBP ArriVent BioPharma	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$45.00
8/13/2026	AVBP ArriVent BioPharma	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$42.00
8/11/2026	LGND Ligand Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Buy (B-)

(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$7.44 per share	N/A
LGND Ligand Pharmaceuticals	$268.09M	20.60	$7.75 per share	35.74	$51.68 per share	5.36
PTCT PTC Therapeutics	$1.01B	5.43	$8.67 per share	7.57	($2.56) per share	-25.64
XENE Xenon Pharmaceuticals	$7.50M	725.41	N/A	N/A	$7.53 per share	7.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$166.31M	-$3.62	N/A	N/A	N/A	N/A	-50.26%	-46.66%	11/16/2026 (Estimated)
LGND Ligand Pharmaceuticals	$124.45M	$9.35	29.62	33.45	2.25	67.88%	20.06%	11.68%	11/5/2026 (Estimated)
PTCT PTC Therapeutics	$682.64M	-$0.58	N/A	30.82	2.05	-3.80%	-362.45%	-1.32%	11/3/2026 (Estimated)
XENE Xenon Pharmaceuticals	-$345.91M	-$4.74	N/A	N/A	N/A	N/A	-43.98%	-41.72%	11/2/2026 (Estimated)

Latest AVBP, XENE, LGND, and PTCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	AVBP ArriVent BioPharma	-$0.9873	-$1.05	-$0.0627	-$1.05	N/A	N/A
8/6/2026	Q2 2026	LGND Ligand Pharmaceuticals	$1.97	$2.37	+$0.40	$2.22	$61.30 million	$63.69 million
8/6/2026	Q2 2026	XENE Xenon Pharmaceuticals	-$1.16	-$1.11	+$0.05	-$1.11	$1.67 million	N/A
7/30/2026	Q2 2026	PTCT PTC Therapeutics	$0.2363	$0.92	+$0.6837	$0.92	$298.63 million	$360.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	14.16	14.16
LGND Ligand Pharmaceuticals	1.16	31.18	30.96
PTCT PTC Therapeutics	N/A	3.39	3.28
XENE Xenon Pharmaceuticals	N/A	21.01	21.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
LGND Ligand Pharmaceuticals	91.28%
PTCT PTC Therapeutics	N/A
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	8.58%
LGND Ligand Pharmaceuticals	5.60%
PTCT PTC Therapeutics	5.30%
XENE Xenon Pharmaceuticals	2.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	77	49.31 million	45.08 million	N/A
LGND Ligand Pharmaceuticals	47	19.94 million	18.82 million	Optionable
PTCT PTC Therapeutics	991	83.46 million	79.04 million	Optionable
XENE Xenon Pharmaceuticals	370	96.67 million	93.85 million	Optionable

AVBP, XENE, LGND, and PTCT Headlines

Recent News About These Companies

Xenon Pharmaceuticals: Epilepsy Got It To $59; Depression Has To Take It From Here

September 13 at 7:06 AM | seekingalpha.com

Engineers Gate Manager LP Grows Stock Holdings in Xenon Pharmaceuticals Inc. $XENE

September 13 at 4:16 AM | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and Immix Biopharma (IMMX)

September 11, 2026 | theglobeandmail.com

112,869 Shares in Xenon Pharmaceuticals Inc. $XENE Bought by Squarepoint Ops LLC

September 11, 2026 | marketbeat.com

Biohaven plummets, a boon for rival Xenon, on a surprise seizure setback

September 10, 2026 | msn.com

Hsbc Holdings PLC Acquires 29,916 Shares of Xenon Pharmaceuticals Inc. $XENE

September 10, 2026 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from Analysts

September 8, 2026 | americanbankingnews.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by Brokerages

September 8, 2026 | marketbeat.com

73,728 Shares in Xenon Pharmaceuticals Inc. $XENE Purchased by Legal & General Group Plc

September 5, 2026 | marketbeat.com

Xenon (XENE) Heads To Europe With Data That Could Reshape Epilepsy Care

September 4, 2026 | insidermonkey.com

Xenon (XENE) Heads To Europe With Data That Could Reshape Epilepsy Care

September 4, 2026 | finance.yahoo.com

The Manufacturers Life Insurance Company Invests $1.75 Million in Xenon Pharmaceuticals Inc. $XENE

September 4, 2026 | marketbeat.com

Corient Private Wealth LP Invests $1.73 Million in Xenon Pharmaceuticals Inc. $XENE

September 4, 2026 | marketbeat.com

Xenon to Present at Wells Fargo Healthcare Conference

September 3, 2026 | globenewswire.com

Xenon Pharmaceuticals Inc. $XENE is Braidwell LP's 10th Largest Position

September 3, 2026 | marketbeat.com

Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) Insider Sells $425,847.00 in Stock

September 2, 2026 | insidertrades.com

Xenon Pharmaceuticals Inc. $XENE Shares Sold by Wellington Management Group LLP

September 2, 2026 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Insider Sells $425,847.00 in Stock

September 1, 2026 | marketbeat.com

Headlands Technologies LLC Buys 23,074 Shares of Xenon Pharmaceuticals Inc. $XENE

September 1, 2026 | marketbeat.com

Alyeska Investment Group L.P. Has $42.11 Million Holdings in Xenon Pharmaceuticals Inc. $XENE

August 31, 2026 | marketbeat.com

Bank of New York Mellon Corp Buys Shares of 421,518 Xenon Pharmaceuticals Inc. $XENE

August 31, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP, XENE, LGND, and PTCT Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$27.97 -0.60 (-2.10%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$27.98 +0.02 (+0.05%)

As of 05:08 AM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Ligand Pharmaceuticals NASDAQ:LGND

$276.98 -3.67 (-1.31%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$277.36 +0.38 (+0.14%)

As of 09/15/2026 07:58 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

PTC Therapeutics NASDAQ:PTCT

$65.65 -0.83 (-1.25%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$65.76 +0.11 (+0.17%)

As of 04:23 AM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Xenon Pharmaceuticals NASDAQ:XENE

$56.28 -1.91 (-3.28%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$56.73 +0.45 (+0.80%)

As of 04:55 AM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVBP, XENE, LGND, and PTCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVBP, XENE, LGND, and PTCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVBP, XENE, LGND, and PTCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP, XENE, LGND, and PTCT Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

Ligand Pharmaceuticals NASDAQ:LGND

PTC Therapeutics NASDAQ:PTCT

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVBP, XENE, LGND, and PTCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVBP, XENE, LGND, and PTCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVBP, XENE, LGND, and PTCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP, XENE, LGND, and PTCT Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

Ligand Pharmaceuticals NASDAQ:LGND

PTC Therapeutics NASDAQ:PTCT

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools